



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

AUG 7 2000

Ms. Anne Bolmström
President
AB BIODISK
Dalvägen 10
S-169 56 Solna
Sweden

Re: K001547
Trade Name: Etest[®] ESBL CT/CTL strip, Etest[®] ESBL TZ/TZL strip
Regulatory Class: II
Product Code: JWY
Dated: July 27, 2000
Received: July 31, 2000

Dear Ms. Bolmström:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in dark ink, appearing to read "Steven Gutman". The signature is fluid and cursive, with the first name "Steven" and last name "Gutman" clearly distinguishable.

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical Laboratory Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

510(k) Number (if known):

Device Name: Etest® ESB� CT/CTL strip:

Cefotaxime (0.25-16µg/ml) / Cefotaxime (0.016-1µg/ml) +clavulanic acid (4µg/ml).

Etest® ESB� TZ/TZL strip:

Ceftazidime (0.5-32µg/ml) / Ceftazidime (0.064-4µg/ml) +clavulanic acid (4µg/ml).

Indications For Use:

For in vitro diagnostic use:

Etest is a quantitative technique for the determination of antimicrobial susceptibility of both non-fastidious Gram negative and Gram positive aerobic bacteria, such as *Enterobacteriaceae*, *Pseudomonas*, *Staphylococcus* and *Enterococcus* species and fastidious bacteria, such as anaerobes, *Pneumococcus* and *Haemophilus* species. The system comprises a predefined antibiotic gradient, which is used to determine the Minimum Inhibitory Concentration (MIC) in µg/ml of individual antibiotics against bacteria as tested on agar media by overnight incubation.

This 510(k) application is for a confirmatory test of Extended Spectrum β-lactamases (ESBLs) in *E. coli*, *K. pneumoniae* and *K. oxytoca* using both Etest ESB� strips with Cefotaxime (0.25-16µg/ml) / Cefotaxime (0.016-1µg/ml) +clavulanic acid (4µg/ml) (CT/CTL) and Etest ESB� TZ/TZL strip with Ceftazidime (0.5-32µg/ml) / Ceftazidime (0.064-4µg/ml) +clavulanic acid (4µg/ml).

The reduction of either Cefotaxime or Ceftazidime MIC by ≥ 3 two-fold dilutions (numeric ratio ≥8) in the presence of clavulanic acid confirms ESB� production.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Woody Dubois
(Division Sign-Off)

Division of Clinical Laboratory Devices

510(k) Number K001547

Prescription Use X
(Per 21 CFR 801.109)

OR

Over-The Counter Use _____